INT38807

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1986
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 29
Total Number 29
Disease Relevance 10.10
Pain Relevance 6.42

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell death (PLA2G6) cytoplasm (PLA2G6)
Anatomy Link Frequency
leukocytes 2
neutrophil 1
PLA2G6 (Homo sapiens)
Pain Link Frequency Relevance Heat
cINOD 149 99.98 Very High Very High Very High
dexamethasone 18 99.86 Very High Very High Very High
Inflammation 542 99.44 Very High Very High Very High
Calcium channel 51 99.40 Very High Very High Very High
antagonist 3 97.82 Very High Very High Very High
cytokine 56 92.16 High High
lidocaine 3 91.68 High High
addiction 3 88.32 High High
Potency 8 87.84 High High
Pain 34 87.68 High High
Disease Link Frequency Relevance Heat
Sepsis 24 99.52 Very High Very High Very High
INFLAMMATION 664 99.44 Very High Very High Very High
Disease 400 97.20 Very High Very High Very High
Diarrhoea 2 93.76 High High
Adhesions 1 92.56 High High
Shock 15 89.64 High High
Polyps 1 88.28 High High
Cardiovascular Disorder Under Development 5 88.24 High High
Bites And Stings 33 87.92 High High
Pain 39 87.68 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Thus inhibitors of PLA2 reduce chemotaxis of leukocytes probably by reducing production of LTB4.
Negative_regulation (inhibitors) of PLA2 in leukocytes
1) Confidence 0.59 Published 1998 Journal Arzneimittelforschung Section Abstract Doc Link 9522038 Disease Relevance 0 Pain Relevance 0.09
PLA2 inhibition by dexamethasone sodium phosphate was factitious, due to the formation of calcium-phosphate complexes.
Negative_regulation (inhibition) of PLA2 associated with dexamethasone
2) Confidence 0.58 Published 1986 Journal Agents Actions Section Abstract Doc Link 3825740 Disease Relevance 0.59 Pain Relevance 0.31
We tested a number of therapeutic agents for their ability to inhibit PLA2 from human septic shock serum.
Negative_regulation (inhibit) of PLA2 associated with sepsis
3) Confidence 0.58 Published 1986 Journal Agents Actions Section Abstract Doc Link 3825740 Disease Relevance 0.53 Pain Relevance 0.30
All agents, with the sole exception of dexamethasone base, inhibited PLA2 activity at concentrations greater than 10(-3) M.
Negative_regulation (inhibited) of PLA2 associated with dexamethasone
4) Confidence 0.58 Published 1986 Journal Agents Actions Section Abstract Doc Link 3825740 Disease Relevance 0.59 Pain Relevance 0.31
This model, joined to the previous one developed for the indole inhibitors of human non-pancreatic secretory phospholipase A2 (hnps-PLA2), an enzyme involved in inflammation processes, will allow for the selection of new strong anti-inflammatory drugs with negligible side effects, at least at the level of hp-PLA2.
Negative_regulation (inhibitors) of PLA2 associated with inflammation and cinod
5) Confidence 0.57 Published 2001 Journal Eur J Med Chem Section Abstract Doc Link 11231046 Disease Relevance 0.20 Pain Relevance 0.15
SB 203347 (2-[2-[3,5-bis (trifluoromethyl) sulfonamido]-4- trifluoromethylphenoxy] benzoic acid) potently inhibits rh type II 14 kDa PLA2 (IC50 = 0.5 microM) but exhibits a 40-fold weaker inhibition of 85 kDa PLA2 (IC50 = 20 microM) using [3H]-AA E. coli as substrate.
Negative_regulation (inhibition) of PLA2
6) Confidence 0.56 Published 1995 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 7562496 Disease Relevance 0.26 Pain Relevance 0.18
Before evaluating the effect of SB 203347 on AA metabolism in intact human neutrophil, we showed that it fully inhibits PLA2 activity in acid extracted-intact human neutrophil homogenate (IC50 = 4.7 microM).
Negative_regulation (inhibits) of PLA2 in neutrophil
7) Confidence 0.56 Published 1995 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 7562496 Disease Relevance 0.28 Pain Relevance 0.15
We have studied the inhibition of four distinct PLA2 enzymes by a range of NSAIDs, using 3H-oleate release from prelabelled membranes of E. coli for assay.
Negative_regulation (inhibition) of PLA2 associated with cinod
8) Confidence 0.53 Published 1994 Journal Agents Actions Section Abstract Doc Link 8079814 Disease Relevance 0.10 Pain Relevance 0.39
We conclude that indomethacin but not the other tested classes of NSAID inhibits the group II PLA2 enzyme in a selective manner and suggest that this may be relevant both to its clinical spectrum and to the design of novel pharmaceutical leads.
Negative_regulation (inhibits) of PLA2 associated with cinod
9) Confidence 0.53 Published 1994 Journal Agents Actions Section Abstract Doc Link 8079814 Disease Relevance 0.06 Pain Relevance 0.46
Palmitoyl trifluormethyl ketone, an inhibitor of Ca(2+) independent phospholipase A2 (iPLA2) and a less potent inhibitor of cytosolic PLA2, dose-dependently reduced the IL-1beta induced PGE2 secretion.
Negative_regulation (inhibitor) of iPLA2
10) Confidence 0.51 Published 2001 Journal Exp. Gerontol. Section Abstract Doc Link 11250126 Disease Relevance 0.73 Pain Relevance 0.44
Palmitoyl trifluormethyl ketone, an inhibitor of Ca(2+) independent phospholipase A2 (iPLA2) and a less potent inhibitor of cytosolic PLA2, dose-dependently reduced the IL-1beta induced PGE2 secretion.
Negative_regulation (inhibitor) of PLA2
11) Confidence 0.51 Published 2001 Journal Exp. Gerontol. Section Abstract Doc Link 11250126 Disease Relevance 0.71 Pain Relevance 0.42
In the case of simultaneously inhibiting PLA2, COX-2/1 and LTA4H, the value of [I]/Ki of COX-2 needed is reduced to 80.
Negative_regulation (inhibiting) of PLA2
12) Confidence 0.47 Published 2008 Journal Mol Syst Biol Section Body Doc Link PMC2673713 Disease Relevance 0.17 Pain Relevance 0.09
This fixed ratio of COX-1/2 inhibition is no longer necessary when PLA2 is inhibited simultaneously (Figure 3B).


Negative_regulation (inhibited) of PLA2
13) Confidence 0.47 Published 2008 Journal Mol Syst Biol Section Body Doc Link PMC2673713 Disease Relevance 0.39 Pain Relevance 0.46
The inhibition of PLA2 and/or COX-1/2 has strong effect on the ratio of PGI2/TXA2.
Negative_regulation (inhibition) of PLA2
14) Confidence 0.47 Published 2008 Journal Mol Syst Biol Section Body Doc Link PMC2673713 Disease Relevance 0.14 Pain Relevance 0
Inhibition of PLA2 can effectively control both PGE2 and LTB4, but will also downregulate all the downstream AA metabolites including vasoactive eicosanoids, which has important physiological functions.
Negative_regulation (Inhibition) of PLA2
15) Confidence 0.47 Published 2008 Journal Mol Syst Biol Section Body Doc Link PMC2673713 Disease Relevance 0.23 Pain Relevance 0.09
SB 203347 (2-[2-[3,5-bis (trifluoromethyl) sulfonamido]-4- trifluoromethylphenoxy] benzoic acid) potently inhibits rh type II 14 kDa PLA2 (IC50 = 0.5 microM) but exhibits a 40-fold weaker inhibition of 85 kDa PLA2 (IC50 = 20 microM) using [3H]-AA E. coli as substrate.
Negative_regulation (inhibits) of PLA2
16) Confidence 0.36 Published 1995 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 7562496 Disease Relevance 0.26 Pain Relevance 0.18
When PLA2 is not inhibited, the ratio of COX-1 and COX-2 inhibition has to be fixed within a narrow range to maintain the ratio of PGI2/TXA2 (Figure 3A).
Negative_regulation (inhibited) of PLA2
17) Confidence 0.35 Published 2008 Journal Mol Syst Biol Section Body Doc Link PMC2673713 Disease Relevance 0.14 Pain Relevance 0
Phase 2 was significantly inhibited by the PLA2 inhibitor, Mepacrine.
Negative_regulation (inhibitor) of PLA2
18) Confidence 0.34 Published 1993 Journal Nippon Sanka Fujinka Gakkai Zasshi Section Abstract Doc Link 8315315 Disease Relevance 0 Pain Relevance 0.07
In addition, the two CaM antagonists W7 and CMZ induced longer lasting rises in influx (Figure 7C, D), that were significantly suppressed by the PLA2 inhibitors BEL and BPB and the specific SOC blocker 2-APB.
Negative_regulation (inhibitors) of PLA2 associated with antagonist
19) Confidence 0.29 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2639705 Disease Relevance 0 Pain Relevance 0.17
Interestingly, a comparison of CHR and CAT sequences with two CaM-binding peptides of iPLA2 reveals marked homologies (Figure 6D).
Negative_regulation (peptides) of iPLA2
20) Confidence 0.28 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2639705 Disease Relevance 0 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox